Five minutes with David Llewellyn from DJS Antibodies
A dynamic new biotech started by Dr David Llewellyn and Dr Joe Illingworth, DJS Antibodies is pioneering the development of novel therapeutics to treat the world’s most critical inflammatory diseases, a class of disease that accounts for more than 50% of deaths worldwide.
Five minutes with Peter Hamley from Samsara Therapeutics
We spoke to Peter Hamley, Chief Scientific Officer of amazing biotech start-up Samsara Therapeutics, who have just moved into the new life science labs at our Wood Centre for Innovation.
Five minutes with Adam Forsyth, CTO of TZ
We spoke to Adam Forsyth CTO of TZ, an Australian start-up at the forefront of electronic locking device development and one of our newer residents at the Oxford Centre for Innovation.
Five minutes with Rachael Grimaldi, founder of Cardmedic
CardMedic must go down as one of the fastest digital start-ups of all time: it went from concept to launch in just 72 hours and this month has signed its first agreement with Kent Surrey Sussex Air Ambulance Trust.
HEAD-TO-HEAD WITH KATIE BEDBOROUGH OF OXFORD VR
HEAD-TO-HEAD WITH KATIE BEDBOROUGH OF OXFORD VR
My interview with Vitaccess Founder & CEO Dr Mark Larkin
Vitaccess have been based here at Oxford Centre for Innovation (OCFI) for nearly two years and, during that time, have seen steep growth. Read on and meet Vitaccess’ CEO and founder, Dr Mark Larkin.
Head-to-head with Clare Lerway at Consultant Connect
Consultant Connect, a second-floor resident of OCFI, has developed a business idea that is dramatically reducing NHS costs. We spoke to Clare Lerway, Account Manager, to find out more…
Head-to-head with Hugh Bettesworth at Mirada Medical
One of the OCFI’s longer-term residents, Mirada Medical is a global brand in advanced medical imaging software, mainly for cancer but for some other diseases too. We spoke to their dynamic CEO, Hugh Bettesworth to find out more.
Absolute Antibody and Kerafast Merge to offer cutting-edge research tools
Absolute Antibody and Kerafast Merge to Increase Access to Unique Reagents and Recombinant Antibody Technology […]
